Table 2.
Serum cytokine profile of children diagnosed with H. pylori positive and negative gastroduodenitis.
| Analyte | H. pylori positive | H. pylori negative | control |
|---|---|---|---|
| Median (pg/ml; 5–95% range) | Median (pg/ml; 5–95% range) | Median (pg/ml; 5–95% range) | |
| IL-1β | 11.10 (3.61–22.30); P < 0.05 | 8.93 (1.57–20.82); P < 0.05 | 2.50 (1.45–4.93) |
| IL2 | 38.24 (18.35–60.99); P < 0.05 | 32.13 (6.30–55.06) | 17.98 (4.67–34.56) |
| IL4 | 64.28 (19.01–87.12); P < 0.05 | 58.32 (30.52–116.86); P < 0.05 | 8.40 (3.30–18.00) |
| IL6 | 28.30 (11.60–51.29) | 25.84 (6.30–64.58) | 16.22 (10.25–76.07) |
| IL8 | 29.00 (9.17–48.30) | 25.59 (8.90–54.76) | 8.32 (3.81–56.00) |
| IL10 | 142.41 (12.51–250.46) | 119.02 (43.21–214.17) | 77.95 (57.01–210.31) |
| IL16 | 2835.29 (91.60–11326.32); P < 0.05 | 2762.31 (381.46–6959.23); P < 0.05 | 678.23 (402.53–2713.07) |
| CCL1 | 203.26 (55.32–276.00); P < 0.05 | 178.84 (86.83–261.92); P < 0.05 | 46.00 (24.62–120.80) |
| CCL2 | 68.41 (3.23–164.97) | 67.02 (12.29–100.79) | 43.23 (34.30–345.63) |
| CCL3 | 24.12 (5.40–36.22) | 21.51 (10.66–65.00) | 28.99 (2.06–87.70) |
| CCL7 | 347.20 (21.11–595.61); P < 0.05 | 309.99 (95.47–550.32); P < 0.05 | 118.14 (61.00–448.84) |
| CCL8 | 87.86 (11.20–333.22) | 115.22 (17.55–284.38) | 78.49 (6.51–141.19) |
| CCL11 | 95.50 (47.20–156.00) | 89.40 (63.60–135.80) | 99.36 (57.30–167.20) |
| CCL13 | 210.14 (13.51–499.87); P < 0.05 | 251.50 (19.57–733.77); P < 0.05 | 34.27 (3.05–210.04) |
| CCL15 | 1654.79 (34.23–41566.08); P < 0.05 | 13334.57 (211.26–43075.98); P < 0.05 | 72.94 (23.65–242.02) |
| CCL17 | 518.65 (29.93–2962.22) | 476.64 (95.91–1426.65) | 243.07 (23.54–1341.02) |
| CCL19 | 1270.66 (47.13–4730.73) | 1075.69 (194.00–2762.13) | 642.28 (120.30–3283.56) |
| CCL20 | 35.41 (3.56–181.76); P < 0.05 | 45.20 (2.33–135.31); P < 0.05 | 4.34 (2.33–8.02) |
| CCL21 | 153.20 (134.20–195.40) | 198.30 (156.20–225.30) | 167.30 (136.20–201.20) |
| CCL22 | 3337.42 (116.17–8142.66); P < 0.05 | 3532.51 (515.56–5486.09); P < 0.05 | 378.38 (5.78–1858.06) |
| CCL23 | 570.75 (23.60–1450.51) | 763.31 (46.20–1901.47) | 252.75 (66.61–731.94) |
| CCL24 | 236.20 (156.50–328.80) | 296.40 (178.30–301.69) | 294.00 (166.00–315.00) |
| CCL25 | 1094.47 (60.90–2606.17) | 351.70 (95.91–1426.65); P < 0.05 | 501.52 (29.40–2019.70) |
| CCL26 | 36.37 (26.20–78.67) | 46.37 (29.30–66.29) | 27.20 (21.27–78.40) |
| CCL27 | 96.67 (84.50–126.30) | 113.34 (82.50–146.20) | 85.60 (76.45–124.30) |
| CXCL1 | 877.52 (106.00–1495.04); P < 0.05 | 813.00 (340.69–2495.34); P < 0.05 | 327.00 (216.83–694.48) |
| CXCL2 | 924.71 (34.76–6357.27); P < 0.05 | 1506.60 (149.96–4479.89); P < 0.05 | 26.52 (5.36–55.10) |
| CXCL5 | 548.17 (126.00–2913.34); P < 0.05 | 758.31 (154.00–3379.31); P < 0.05 | 167.00 (123.00–209.00) |
| CXCL6 | 151.67 (34.00–479.22); P < 0.05 | 134.32 (64.54–711.35); P < 0.05 | 34.00 (34.00–108.23) |
| CXCL9 | 973.81 (58.21–2921.36) | 876.86 (148.47–5175.09) | 313.88 (114.60–1303.63) |
| CXCL10 | 568.92 (85.11–2082.65); P < 0.05 | 686.86 (89.18–3958.80); P < 0.05 | 87.00 (50.01–99.84) |
| CXCL11 | 135.81 (6.18–457.00); P < 0.05 | 126.97 (19.55–949.43); P = 0.000004 | 3.70 (1.78–12.26) |
| CXCL12 | 4423.42 (163.20–7225.97); P < 0.05 | 3659.66 (875.50–6827.47); P < 0.05 | 107.70 (89.40–1365.15) |
| CXCL16 | 1103.74 (9.53–2096.30); P < 0.05 | 1291.65 (128.47–1931.20); P < 0.05 | 171.11 (8.88–442.83) |
| CXCL13 | 86.49 (10.00–218.93) | 97.56 (7.02–177.21) | 11.05 (3.79–208.33) |
| CX3CL1 | 120.30 (67.10–176.50) | 127.90 (66.80–150.30) | 100.70 (68.30–167.20) |
| GM-CSF | 8.30 (2.80–456.83) | 33.59 (12.88–230.11); P < 0.05, *P < 0.05 | 13.3 (10.20–15.30) |
| INF-γ | 145.72 (15.26–243.31) | 132.90 (36.60–245.16) | 83.00 (40.25–164.07) |
| MIF | 375.98 (78.00–46690.84); P < 0.05 | 6641.92 (525.81–89114.28); P < 0.05, *P < 0.05 | 23.67 (9.28–207.56) |
| TNF-α | 74.57 (2.56–131.86); P < 0.05 | 62.12 (24.66–104.25); P < 0.05 | 10.23 (3.45–36.97) |
P—significance between gastroduodenitis group and healthy control, Steel-Dwass test.
*
P—significance gastroduodenitis groups, Steel-Dwass test.